Articles with public access mandates - Timothy M. MillerLearn more
Not available anywhere: 2
Review
Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial
M Cudkowicz, A Genge, N Maragakis, S Petri, L van den Berg, VV Aho, ...
The Lancet Neurology 20 (10), 821-831, 2021
Mandates: National Institute for Health Research, UK
Review
Incidence of amyotrophic lateral sclerosis in older adults
A Camacho‐Soto, S Searles Nielsen, IM Faust, RC Bucelli, TM Miller, ...
Muscle & nerve 66 (3), 289-296, 2022
Mandates: US National Institutes of Health, Doris Duke Charitable Foundation
Available somewhere: 83
Review
Distinct tau prion strains propagate in cells and mice and define different tauopathies
DW Sanders, SK Kaufman, SL DeVos, AM Sharma, H Mirbaha, A Li, ...
Neuron 82 (6), 1271-1288, 2014
Mandates: US National Institutes of Health, UK Medical Research Council
Review
Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds
BB Holmes, SL DeVos, N Kfoury, M Li, R Jacks, K Yanamandra, ...
Proceedings of the National Academy of Sciences 110 (33), E3138-E3147, 2013
Mandates: US National Institutes of Health
Review
RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and frontotemporal dementia
T Zu, Y Liu, M Bañez-Coronel, T Reid, O Pletnikova, J Lewis, TM Miller, ...
Proceedings of the National Academy of Sciences 110 (51), E4968-E4977, 2013
Mandates: US National Institutes of Health, Government of Spain
Review
TDP-43 mutant transgenic mice develop features of ALS and frontotemporal lobar degeneration
I Wegorzewska, S Bell, NJ Cairns, TM Miller, RH Baloh
Proceedings of the National Academy of Sciences 106 (44), 18809-18814, 2009
Mandates: US National Institutes of Health
Review
An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study
TM Miller, A Pestronk, W David, J Rothstein, E Simpson, SH Appel, ...
The Lancet Neurology 12 (5), 435-442, 2013
Mandates: US National Institutes of Health
Review
Genome-wide analyses identify KIF5A as a novel ALS gene
A Nicolas, KP Kenna, AE Renton, N Ticozzi, F Faghri, R Chia, ...
Neuron 97 (6), 1267-1288, 2018
Mandates: US National Institutes of Health, US Department of Veterans Affairs, Howard …
Review
C9orf72 is required for proper macrophage and microglial function in mice
JG O’rourke, L Bogdanik, A Yáñez, D Lall, AJ Wolf, A Muhammad, R Ho, ...
Science 351 (6279), 1324-1329, 2016
Mandates: US National Institutes of Health
Review
Tau kinetics in neurons and the human central nervous system
C Sato, NR Barthélemy, KG Mawuenyega, BW Patterson, BA Gordon, ...
Neuron 97 (6), 1284-1298. e7, 2018
Mandates: US National Institutes of Health, Alzheimers's UK
Review
Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS
T Miller, M Cudkowicz, PJ Shaw, PM Andersen, N Atassi, RC Bucelli, ...
New England Journal of Medicine 383 (2), 109-119, 2020
Mandates: National Institute for Health Research, UK
Review
Trial of sodium phenylbutyrate–taurursodiol for amyotrophic lateral sclerosis
S Paganoni, EA Macklin, S Hendrix, JD Berry, MA Elliott, S Maiser, ...
New England Journal of Medicine 383 (10), 919-930, 2020
Mandates: US National Institutes of Health
Review
Tau reduction prevents neuronal loss and reverses pathological tau deposition and seeding in mice with tauopathy
SL DeVos, RL Miller, KM Schoch, BB Holmes, CS Kebodeaux, ...
Science translational medicine 9 (374), eaag0481, 2017
Mandates: US National Institutes of Health
Review
Tau prion strains dictate patterns of cell pathology, progression rate, and regional vulnerability in vivo
SK Kaufman, DW Sanders, TL Thomas, AJ Ruchinskas, J Vaquer-Alicea, ...
Neuron 92 (4), 796-812, 2016
Mandates: US National Institutes of Health
Review
Antisense reduction of tau in adult mice protects against seizures
SL DeVos, DK Goncharoff, G Chen, CS Kebodeaux, K Yamada, ...
Journal of Neuroscience 33 (31), 12887-12897, 2013
Mandates: US National Institutes of Health
Review
Antisense oligonucleotides: translation from mouse models to human neurodegenerative diseases
KM Schoch, TM Miller
Neuron 94 (6), 1056-1070, 2017
Mandates: US National Institutes of Health
Review
TREM2 variant p. R47H as a risk factor for sporadic amyotrophic lateral sclerosis
J Cady, ED Koval, BA Benitez, C Zaidman, J Jockel-Balsarotti, P Allred, ...
JAMA neurology 71 (4), 449-453, 2014
Mandates: US National Institutes of Health
Review
Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice
ED Koval, C Shaner, P Zhang, X Du Maine, K Fischer, J Tay, BN Chau, ...
Human molecular genetics 22 (20), 4127-4135, 2013
Mandates: US National Institutes of Health
Review
Antisense oligonucleotides extend survival and reverse decrement in muscle response in ALS models
A McCampbell, T Cole, AJ Wegener, GS Tomassy, A Setnicka, BJ Farley, ...
The Journal of clinical investigation 128 (8), 3558-3567, 2018
Mandates: US National Institutes of Health
Review
Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia
OH Tam, NV Rozhkov, R Shaw, D Kim, I Hubbard, S Fennessey, N Propp, ...
Cell reports 29 (5), 1164-1177. e5, 2019
Mandates: US National Institutes of Health, Chan Zuckerberg Initiative
Publication and funding information is determined automatically by a computer program